Analysts Set LENZ Therapeutics, Inc. (NASDAQ:LENZ) PT at $35.40

LENZ Therapeutics, Inc. (NASDAQ:LENZ) has received an average recommendation of “Buy” from the seven ratings firms that are covering the stock, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $35.40.

Several equities research analysts have recently weighed in on LENZ shares. Raymond James assumed coverage on LENZ Therapeutics in a research note on Friday, September 27th. They issued an “outperform” rating and a $37.00 price objective on the stock. William Blair upgraded shares of LENZ Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Finally, HC Wainwright reiterated a “buy” rating and set a $38.00 target price on shares of LENZ Therapeutics in a research report on Thursday, November 7th.

Hedge Funds Weigh In On LENZ Therapeutics

Large investors have recently modified their holdings of the stock. SG Americas Securities LLC acquired a new position in shares of LENZ Therapeutics in the third quarter worth approximately $107,000. MetLife Investment Management LLC acquired a new stake in LENZ Therapeutics during the 3rd quarter worth about $182,000. GSA Capital Partners LLP bought a new position in shares of LENZ Therapeutics in the 3rd quarter worth about $246,000. Squarepoint Ops LLC acquired a new position in shares of LENZ Therapeutics in the 2nd quarter valued at about $181,000. Finally, Jane Street Group LLC bought a new stake in shares of LENZ Therapeutics during the 3rd quarter valued at about $286,000. 54.32% of the stock is owned by institutional investors.

LENZ Therapeutics Price Performance

LENZ opened at $30.28 on Friday. The business has a fifty day simple moving average of $31.60 and a 200-day simple moving average of $24.87. LENZ Therapeutics has a fifty-two week low of $14.42 and a fifty-two week high of $38.93.

LENZ Therapeutics (NASDAQ:LENZ) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.09. During the same quarter last year, the business posted ($1.33) EPS. As a group, equities analysts expect that LENZ Therapeutics will post -2.09 EPS for the current year.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.